Sare Gülfem Özlü1,2, Aysun Çaltık3, Özlem Aydoğ3, Mehmet Bülbül3, Gülay Demircin3, Evrim Çakıcı3, Nilüfer Arda4, Ayşe Öner3. 1. Department of Pediatric Nephrology, Dr Sami Ulus Childrens and Maternity Hospital, Ankara, Turkey. saredr@gmail.com. 2. Department of Pathology, Sami Ulus Childrens and Maternity Hospital, Ankara, Turkey. saredr@gmail.com. 3. Department of Pediatric Nephrology, Dr Sami Ulus Childrens and Maternity Hospital, Ankara, Turkey. 4. Department of Pathology, Sami Ulus Childrens and Maternity Hospital, Ankara, Turkey.
Abstract
BACKGROUND: Crescentic glomerulonephritis (CsGN) is characterized by crescents in 50% or more of glomeruli and clinically by a sudden and progressive decline in renal function. METHODS: We evaluated the etiology, clinical features, prognostic factors and long-term outcome of CsGN. Between January 2000 and December 2010, 45 children (26 girls, 19 boys) with biopsy-proven CsGN (>50% crescents) were investigated retrospectively. RESULTS: The mean age of the patients was 130.86±33.77 months. The mean duration of symptoms prior to diagnosis was 26±12 days (4-40 days). Most of the children had hypertension (62.2%), macroscopic hematuria (73.3%), oligoanuria (44.4%), edema (51.1%) and purpuric rash (40%) at presentation. The final clinical status of the patients was complete remission (n=21), partial remission (n=5) or chronic kidney disease (n=19). Adverse outcomes were significantly associated with a long duration between the onset of symptoms and treatment (P=0.038), the presence of oligoanuria (P=0.006), a severe decreased glomerular filtration rate (GFR <30 mL/min/1.73m²) and the need for dialysis (P=0.003) on admission, the ratio of crescents (>75%) (P=0.03), and the ratio of fibrous crescents (P=0.015). CONCLUSION: The outcome of CsGN in children continues to be poor, and it should be treated as a renal emergency.
BACKGROUND: Crescentic glomerulonephritis (CsGN) is characterized by crescents in 50% or more of glomeruli and clinically by a sudden and progressive decline in renal function. METHODS: We evaluated the etiology, clinical features, prognostic factors and long-term outcome of CsGN. Between January 2000 and December 2010, 45 children (26 girls, 19 boys) with biopsy-proven CsGN (>50% crescents) were investigated retrospectively. RESULTS: The mean age of the patients was 130.86±33.77 months. The mean duration of symptoms prior to diagnosis was 26±12 days (4-40 days). Most of the children had hypertension (62.2%), macroscopic hematuria (73.3%), oligoanuria (44.4%), edema (51.1%) and purpuric rash (40%) at presentation. The final clinical status of the patients was complete remission (n=21), partial remission (n=5) or chronic kidney disease (n=19). Adverse outcomes were significantly associated with a long duration between the onset of symptoms and treatment (P=0.038), the presence of oligoanuria (P=0.006), a severe decreased glomerular filtration rate (GFR <30 mL/min/1.73m²) and the need for dialysis (P=0.003) on admission, the ratio of crescents (>75%) (P=0.03), and the ratio of fibrous crescents (P=0.015). CONCLUSION: The outcome of CsGN in children continues to be poor, and it should be treated as a renal emergency.
Authors: Amr A El-Husseini; Hussein A Sheashaa; Alaa A Sabry; Fatma E Moustafa; Mohamed A Sobh Journal: Int Urol Nephrol Date: 2005 Impact factor: 2.370
Authors: Joseph G Maliakkal; M John Hicks; Mini Michael; David T Selewski; Katherine Twombley; Michelle N Rheault; Meredith Seamon; Jason M Misurac; Cheryl L Tran; Loretta Reyes; Joseph T Flynn; Ali M Onder; Alexandru R Constantinescu; Vaishali Singh; Cynthia Pan; Abiodun Omoloja; Qiang Wu; William E Smoyer; Guillermo Hidalgo; Scott E Wenderfer Journal: J Clin Med Date: 2020-07-26 Impact factor: 4.241
Authors: Farah A Falix; Michiel J S Oosterveld; Sandrine Florquin; Jaap W Groothoff; Antonia H M Bouts Journal: Pediatr Nephrol Date: 2017-03-09 Impact factor: 3.714
Authors: Faisal G Mosaad; Omar Mohammed Saggaf; Khaled T Aletwady; Khaled Y Mohammed Jan; Khalid Al-Qarni; Rakan S Al-Harbi; Osama Y Safdar Journal: Saudi Med J Date: 2018-04 Impact factor: 1.484